RxDoctor Payments Data

Kishan Parikh, MD

Advanced Heart Failure and Transplant Cardiology · Raleigh, NCNPI 1780813782

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $95,029 of the $157,572 with a category attached, or 60.3%. 25 manufacturers reported payments, led by United Therapeutics Corporation at 51.4% of the total. 2025 is the largest year on record at $83,831, more than ten times the $4,953 reported in 2019.

$157,572in general payments, 2019–2025

Across 289 payments — averaging $545.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$81K
  • Merck$50K
  • Actelion Pharmaceuticals US, Inc.$15K
  • Boehringer Ingelheim$6K
  • Lilly USA, LLC$3K
  • Bayer$2K
  • plus $2K from 19 others
$161,234in research payments, 2019–2025

Across 77 payments — averaging $2093.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$83K
  • Amgen$30K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$27K
  • United Therapeutics Corporation$9K
  • Boehringer Ingelheim International GmbH$7K
  • Boston Scientific$4K
  • plus $1K from 1 others

What the payments were for

  • Consulting fees$41,12026%
  • Speaking & faculty fees$95,02960%
  • Travel & lodging$15,44910%
  • Food & beverage$5,8964%
  • Education$790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$157,572 in reported general payments places this provider in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

See all advanced heart failure and transplant cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$55,633
Medicare patients
183
Services billed
4,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil175$4,332,057
OpsumitMacitentan250$3,248,905
WinrevairSotatercept-Csrk132$2,476,184
UptraviSelexipag100$2,409,560
VyndamaxTafamidis58$1,381,543
AdempasRiociguat20$293,771
Ambrisentan95$243,260
JardianceEmpagliflozin189$166,613
FarxigaDapagliflozin Propanediol106$81,120
EliquisApixaban89$74,234
EntrestoSacubitril/Valsartan77$67,630
Tadalafil131$67,196
XareltoRivaroxaban17$26,020
Sildenafil Citrate154$25,822
Torsemide230$8,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$14,816$5,658,465350 claims
MerckWinrevair$49,742$2,476,184132 claims
PfizerVyndamax, Eliquis$82$1,455,777147 claims
BayerAdempas$2,075$293,77120 claims
Boehringer IngelheimJardiance$5,594$166,613189 claims
AstraZenecaFarxiga$233$81,120106 claims
NovartisEntresto$143$67,63077 claims
Johnson & JohnsonXarelto$46$26,02017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.

Other advanced heart failure and transplant cardiology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →